January 25, 2018

In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease.

Read Biogen Report Jan. 25, 2018

BIIB054 on ClinicalTrials.gov